FITC-Labeled B7-H3/CD276 Fc Chimera: The "Classical Dual-Functional Probe" for Immune Checkpoint Research

This protein is a recombinant fusion probe designed to combine detection and preliminary functional studies, consisting of three core functional modules:

The core of the probe is the extracellular immunoglobulin-like domain of human B7-H3 protein. B7-H3 (CD276) is a type I transmembrane protein whose extracellular portion contains two immunoglobulin V-like and C-like domains. This module retains the potential to bind to putative B7-H3 receptors (which remain incompletely characterized but may include TREM-like transcript 2, among others), enabling specific recognition and binding to cells expressing B7-H3 or interaction with soluble B7-H3.

The B7-H3 extracellular domain is genetically fused with the Fc fragment of human IgG. This design is key to the probe's "dual functionality":

Detection Flexibility and Signal Amplification: The Fc fragment provides a universal interface for any labeled anti-Fc secondary antibody. This allows users to not only directly utilize the FITC signal for detection but also switch to other fluorescence channels (e.g., PE, APC) or amplify signals via secondary antibodies for low-expression samples.

Functional Mimicry and Crosslinking Studies: The Fc fragment enables multivalent crosslinking of the probe on cell surfaces using anti-Fc antibodies. This can be used to preliminarily mimic membrane-bound B7-H3 interactions with its receptors, study the potential regulatory effects of such crosslinking on receptor-positive cells (e.g., T cells), or investigate endocytic pathways.

The probe is covalently labeled with fluorescein isothiocyanate (FITC). FITC emits green fluorescence when excited by 488 nm laser light, offering the following advantages:

Universal and Cost-Effective Basic Detection: Ensures direct usability on nearly all flow cytometry and imaging platforms, simplifying operations and reducing costs for routine detection and preliminary screening.

Compatibility with Functional Experiments: During functional experiments involving cell activation or co-culture, the FITC-labeled probe can serve as a tracer to simultaneously monitor binding and cellular behavior changes.

This probe is a "practical multifunctional entry-level tool" for studying complex immune checkpoint molecules. The B7-H3 extracellular domain is a "universal key" for recognizing this critical immune "switch"; FITC is a "universal indicator light" providing basic feedback; and the Fc Chimera acts as a "multifunctional adapter," capable of both adapting detection signals to different equipment (fluorescence channels) and translating the "key insertion" into observable "mechanical linkages" (functional effects). This enables users to address two fundamental questions—"Where is B7-H3?" and "What might B7-H3 do?"—with a single tool.

The probe supports a coherent workflow from simple phenotypic detection to preliminary functional studies.

Direct Flow Cytometry and Imaging Analysis: After one-step staining, flow cytometry can quantitatively analyze the proportion of B7-H3-positive cells and expression intensity (MFI), while immunofluorescence microscopy can visualize B7-H3 distribution on cell membranes or in tissues. This is the foundational method for assessing B7-H3 expression levels on tumor cells, tumor-associated fibroblasts, or infiltrating immune cells.

Freeing Up Multicolor Analysis Channels: In complex immunophenotyping, if the FITC channel is occupied by other critical markers, the Fc tag allows indirect detection using differently labeled anti-Fc secondary antibodies, transferring the B7-H3 signal to other channels for more flexible multiparameter panel design.

Enhancing Low-Abundance Signals: For low-expressing B7-H3 cell types or soluble B7-H3 detection, indirect methods or biotin-streptavidin systems can amplify signals.

Studying Ligand-Receptor Binding: As a soluble B7-H3 ligand (or ligand mimic), the probe can be used in binding experiments with putative receptor-positive cells (e.g., certain T cell subsets), validating interactions via flow cytometry or imaging.

Preliminary Functional Modulation Studies: Co-incubating the probe with cells expressing potential B7-H3 receptors (e.g., T cells) and crosslinking with anti-Fc antibodies can preliminarily observe effects on T cell proliferation, activation marker expression (e.g., CD69, CD25), or cytokine secretion, providing initial evidence of B7-H3's immunomodulatory functions.

Competitive Blockade Experiments: Used to validate whether other B7-H3-targeting therapeutics (e.g., monoclonal antibodies, bispecific antibodies) function by blocking B7-H3-receptor interactions.

The probe has broad utility in tumor immunology, autoimmune diseases, and inflammatory disease research.

Assessing B7-H3 Tumor Expression Profiles: Systematically detect B7-H3 expression levels across tumor types (e.g., non-small cell lung cancer, breast cancer, prostate cancer, neuroblastoma, glioblastoma) and subtypes/stages, analyzing correlations with clinicopathological features and prognosis.

Decoding Tumor Microenvironment Composition: Using multicolor flow cytometry or immunofluorescence, simultaneously analyze B7-H3 expression on tumor cells, tumor-associated macrophages, dendritic cells, and vascular endothelial cells to reveal complex spatial distribution patterns.

Studying Immunosuppressive Functions: Leveraging the probe's functional mode, investigate the inhibitory effects of tumor- or stroma-derived B7-H3 on T cell and NK cell anti-tumor functions in vitro co-culture systems.

Target Validation and Screening: Confirm B7-H3 expression on candidate tumor models, a preliminary step in drug development.

Mechanistic Exploration: As a competitor, evaluate whether therapeutic antibodies function by blocking B7-H3-receptor interactions or use its crosslinking properties to mimic antibody-induced receptor clustering.

Target Expression Assessment: Precisely evaluate B7-H3 expression levels and heterogeneity in patient biopsy samples or circulating tumor cells during screening.

Treatment Monitoring: Dynamically track post-treatment B7-H3 expression changes to study antigen escape potential.

Bispecific Antibody Development: Serve as a standardized target-binding module to validate the binding activity of the B7-H3-targeting arm in bispecific antibodies.

Exploring B7-H3's Immunomodulatory Roles: In rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease models, detect B7-H3 expression patterns in diseased tissues and use the probe to preliminarily study its potential role in suppressing excessive autoimmune responses or promoting inflammation resolution. B7-H3 may exhibit anti-inflammatory effects in certain contexts.

Studying Transplant Tolerance Induction: The B7-H3 pathway is implicated in transplant tolerance. This probe can be used to investigate its role in regulating graft rejection or inducing regulatory T cells.

In the era of booming immunotherapy, such foundational yet flexible tools hold enduring value in connecting phenotypic and functional studies.

The probe can serve as "bait" protein, combined with post-binding crosslinking and immunoprecipitation or mass spectrometry, to help identify and validate novel B7-H3-interacting receptors or co-receptors, addressing long-standing key questions in the field.

Use the probe to study dynamic changes in B7-H3 expression on tumor cells and in the microenvironment before and after radiotherapy, chemotherapy, targeted therapy, or immune checkpoint inhibitor treatment, exploring its role as a marker of immunogenic cell death or adaptive resistance mechanism to inform combination therapy design.

Integrate into multiplex immunofluorescence analyses to precisely map spatial relationships between B7-H3 expression and T cell infiltration, exhaustion states, angiogenesis, and cell proliferation in situ, constructing high-dimensional tumor immune ecosystem maps.

Develop highly sensitive circulating tumor cell or exosome B7-H3 detection methods based on this probe, exploring its potential as a liquid biopsy biomarker for non-invasive treatment monitoring.

Promote standardization of probe detection protocols to provide prototypes for potential patient stratification or companion diagnostic assays in future B7-H3-targeting clinical trials.

As it encompasses co-stimulation/co-inhibition, immune checkpoints, antibody engineering, flow cytometry, and functional assays, the probe can serve as a classic teaching case in advanced immunology or tumor immunology courses, demonstrating the complete research workflow from molecular phenotyping to functional validation.

FITC-Labeled B7-H3/CD276 Fc Chimera is an exquisitely designed "classic dual-functional probe" in the immune checkpoint research field. Facing the complexity of B7-H3—a molecule with multifaceted functions and incompletely characterized receptors—the probe does not pursue extreme performance in a single dimension. Instead, it ingeniously integrates signal flexibility and preliminary functional manipulation into a classic FITC-based detection platform via the Fc Chimera structure. This enables it to serve as both a reliable "scout" mapping B7-H3 distribution in the tumor and immune battlefield and a preliminary "disruptor" probing the functional circuitry of this immune switch. From charting B7-H3 landscapes in the tumor immune microenvironment to aiding the development of revolutionary targeted drugs and cell therapies; from exploring protective mechanisms in autoinflammation to serving as an educational bridge connecting phenotype and function—this "dual-functional tool," with its pragmatic and adaptable nature, provides researchers a solid and effective starting point for deepening their understanding of B7-H3, an important yet complex immune molecule. In the era of precision immunotherapy, such tools will continue to play their unique foundational role at the frontiers of target validation, mechanistic exploration, and translational research.